Recon: AbbVie’s schizophrenia drug from $9B buyout falters in 2 studies; FDA lifts hold on Novavax flu-COVID vaccine trials
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States